Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma
Status:
Completed
Trial end date:
2019-01-14
Target enrollment:
Participant gender:
Summary
Phase I trial aimed to determine the Maximum Tolerable Dose of the BV in combination with
ESHAP in relapsed/resistant Hodgkin Lymphona patients and to evaluate response to treatment
with BV-ESHAP as salvage regimen prior to autologous stem cell transplantation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea